Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AngioBiomed
Hennigsdorf, Brandenburg, Germanyangiobiomed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AngioBiomed GmbH is a German biotechnology company based in Hennigsdorf and a wholly-owned subsidiary of Deutsche Biotech Innovativ AG (DBI AG). Founded in 2015, the company specializes in developing antibody-based therapies for cancer, with a focus on inhibiting tumor-induced angiogenesis. Its lead program, AB2302, is a monoclonal antibody designed to neutralize adrenomedullin (ADM), a peptide hormone that promotes the growth of blood vessels that supply tumors. By blocking ADM, AB2302 aims to starve tumors of oxygen and nutrients, serving as a complementary treatment to standard cancer therapies. The candidate is currently in preclinical development and has demonstrated efficacy in reducing tumor progression in animal models.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Biotech
Beyond the preview
Go deeper on AngioBiomed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AngioBiomed.